Abstract
Introduction
Pulmonary arterial hypertension (PAH) is a rare but fatal disease that
severely compromises pulmonary and cardiovascular function. New treatment
guidelines and increasing awareness of PAH are rapidly expanding the treatable
patient population. Once the exclusive domain of specialty pharma and small
biotech fi rms, PAH is now attracting the attention of a wider scope of
companies looking to enter this compact but lucrative market.
Get the Answers You Need to Shape Your Strategy
Actelion's Tracleer (bosentan) was the fi rst oral drug to gain widespread
approval for PAH and is currently the dominant player in the PAH market.
However, a signifi cant need for conveniently formulated, effi cacious, and
reasonably priced alternatives remains.
Which agents-established and emerging-are poised to challenge Tracleer?
A growing treatable patient population and a shift from monotherapy to a
multimodal treatment approach are expanding the PAH market.
What other attractive qualities does the PAH market have, and what opportunities does it present for drug manufacturers?
Pfizer has expanded the reach of its lifestyle drug Viagra (sildenafi l) by
gaining approval to include PAH in its list of indications.
Which other manufacturers plan to follow the same strategy with their established therapies?
Scope
- Overview of PAH: disease characteristics, diagnosis, prevalent
cases, risk factors, disease pathways, and drug targets.
- Approved drug therapies: Flolan, Tracleer, Revatio, Remodulin,
Ventavis, Procylin, combination therapy.
- Promising new therapies: novel endothelin receptor antagonists,
reformulated prostacyclin analogues, PDE-5 inhibitors, vasoactive intestinal
peptide derivatives, serotonin pathway antagonists, tyrosine kinase
inhibitors, and others.
- Outlook: market drivers and constraints, and forecast of the PAH
market through 2010.
Mentioned in This Spectrum Report
Companies
- Actelion
- Astellas Pharma
- Bayer-Schering AG
- Biogen Idec
- Cotherix
- Eli Lilly
- Encysive
- Epix
- Forest
- Gilead Sciences
- GlaxoSmithKline
- ICOS
- Kaken Pharmaceuticals
- Lundbeck
- mondoBiotech
- Myogen
- Novartis
- Pfi zer
- PR Pharmaceuticals
- United Therapeutics
| 
View Cart
